

Maurizio Fava

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/4614585/publications.pdf](https://exaly.com/author-pdf/4614585/publications.pdf)

Version: 2025-02-01

502

PR articles

39,486

PR citations

3174

87

PR h-index

2543

192

g-index

550

documents

48133

doc citations

2897

96

h-index

47604

citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , 2025, 40, 138-147.	1.2	11
2	Novel multi-modal methodology to investigate placebo response in major depressive disorder. <i>Journal of Affective Disorders</i> , 2025, 368, 1-7.	4.5	0
3	A novel artificial intelligence-based methodology to predict non-specific response to treatment. <i>Psychiatry Research</i> , 2025, 348, 116506.	3.1	1
4	Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder. <i>JAMA Network Open</i> , 2025, 8, e2514278.	6.6	2
5	Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). <i>Journal of Affective Disorders</i> , 2025, 390, 119836.	4.5	0
6	Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study. <i>Brain, Behavior, & Immunity - Health</i> , 2024, 35, 100717.	2.4	11
7	Dysregulated inflammatory physiology and cognitive impairment in individuals with depression exhibiting a pro-inflammatory phenotype and receiving omega-3 polyunsaturated fatty acids. <i>Psychoneuroendocrinology</i> , 2024, 160, 106713.	2.7	0
8	Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. <i>Molecular Psychiatry</i> , 2024, 29, 2287-2295.	7.8	33
9	Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. <i>Neuropsychopharmacology</i> , 2024, 49, 1437-1447.	5.3	26
10	Using Drift Diffusion and RL Models to Disentangle Effects of Depression On Decision-Making vs. Learning in the Probabilistic Reward Task. <i>Computational Psychiatry</i> , 2024, 8, .	1.9	4
11	EEG measures of brain arousal in relation to symptom improvement in patients with major depressive disorder: Results from a randomized placebo-controlled clinical trial. <i>Psychiatry Research</i> , 2024, 342, 116165.	3.1	2
12	Inflammatory biomarker findings from a randomized controlled trial of heated yoga for depression. <i>Brain Behavior and Immunity Integrative</i> , 2024, 8, 100089.	1.6	2
13	The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. <i>World Psychiatry</i> , 2023, 22, 48-74.	53.0	96
14	Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators. <i>Neuropsychopharmacology</i> , 2023, 48, 929-935.	5.3	21
15	Ages at menarche and menopause, hormone therapy, and the risk of depression. <i>General Hospital Psychiatry</i> , 2023, 83, 35-42.	2.6	30
16	Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. <i>American Journal of Psychiatry</i> , 2023, 180, 241-251.	8.8	46
17	Esmethadone-HCl (REL-1017): a promising rapid antidepressant. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 1463-1476.	2.7	25
18	How should we design future mechanistic and/or efficacy clinical trials?. <i>Neuropsychopharmacology</i> , 2023, 49, 197-204.	5.3	14

#	ARTICLE	IF	CITATIONS
19	Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo. <i>Translational Psychiatry</i> , 2023, 13, .	5.2	9
20	Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial. <i>Brain, Behavior, & Immunity - Health</i> , 2023, 32, 100666.	2.4	9
21	A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence. <i>Psychiatry Research</i> , 2023, 327, 115367.	3.1	6
22	Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. <i>Translational Psychiatry</i> , 2023, 13, .	5.2	9
23	Suppression and acceptance in unipolar depression: Short-term and long-term effects on emotional responding. <i>British Journal of Clinical Psychology</i> , 2022, 61, 1-17.	5.2	1
24	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2022, 91, 550-560.	5.4	22
25	A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. <i>Journal of Affective Disorders</i> , 2022, 296, 549-558.	4.5	20
26	A multi-pronged investigation of option generation using depression, PET and modafinil. <i>Brain</i> , 2022, 145, 1854-1865.	8.4	8
27	The United States index of socioeconomic deprivation for individuals (USIDep). <i>Personalized Medicine in Psychiatry</i> , 2022, 31-32, 100091.	0.4	4
28	Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design. <i>Statistics in Medicine</i> , 2022, 41, 2166-2190.	1.7	2
29	Bullying, Psychological, and Physical Trauma During Early Life Increase Risk of Major Depressive Disorder in Adulthood: A Nationwide Community Sample of Korean Adults. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.4	8
30	Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response. <i>Biological Psychiatry</i> , 2022, 92, 533-542.	5.4	31
31	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2022, 149, 243-251.	2.9	5
32	Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 305, 55-64.	4.5	23
33	Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study. <i>Biological Psychiatry</i> , 2022, 92, 236-245.	5.4	28
34	Diminished frontal pole size and functional connectivity in young adults with high suicidality. <i>Journal of Affective Disorders</i> , 2022, 310, 484-492.	4.5	16
35	Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 140-145.	1.7	2
36	Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. <i>CNS Spectrums</i> , 2022, 27, 236-236.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Relationships among subclinical psychotic symptoms in young adults over time. <i>Psychiatry Research</i> , 2022, 314, 114617.	3.1	1
38	The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4828-4838.	2.6	3
39	Constricted semantic relations in acute depression. <i>Journal of Affective Disorders</i> , 2022, 311, 565-571.	4.5	3
40	A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 827-838.	2.7	7
41	Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors. <i>Pharmaceuticals</i> , 2022, 15, 997.	4.2	24
42	International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. <i>Molecular Psychiatry</i> , 2022, 27, 5096-5112.	7.8	67
43	Early psychiatric referral after attempted suicide helps prevent suicide reattempts: A longitudinal national cohort study in South Korea. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.4	3
44	Associations Between Genetic Risk for Adult Suicide Attempt and Suicidal Behaviors in Young Children in the US. <i>JAMA Psychiatry</i> , 2022, 79, 971.	12.4	29
45	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	4.2	72
46	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 20-28.	1.2	10
47	Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress. <i>Journal of Attention Disorders</i> , 2021, 25, 340-354.	2.8	18
48	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. <i>Depression and Anxiety</i> , 2021, 38, 57-66.	4.0	11
49	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	2.7	54
50	Altered temporal, but intact spatial, features of transient network dynamics in psychosis. <i>Molecular Psychiatry</i> , 2021, 26, 2493-2503.	7.8	25
51	Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. <i>Journal of Psychiatric Research</i> , 2021, 133, 73-81.	2.9	30
52	Anxious attachment is associated with heightened responsivity of a parietofrontal cortical network that monitors peri-personal space. <i>NeuroImage: Clinical</i> , 2021, 30, 102585.	3.3	22
53	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 282, 602-610.	4.5	9
54	Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 214-226.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Increased risk of depression before and after unilateral or bilateral oophorectomy: A self-controlled case series study using a nationwide cohort in South Korea. <i>Journal of Affective Disorders</i> , 2021, 285, 47-54.	4.5	3
56	Relationship between cannabis use and psychotic experiences in college students. <i>Schizophrenia Research</i> , 2021, 231, 198-204.	2.3	16
57	Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder. <i>International Journal of Clinical Practice</i> , 2021, 75, .	3.0	10
58	Obsessive Thought, Compulsive Behavior, and Their Associations With Suicide Ideation and Attempts and Major Depressive Disorder. <i>Journal of Nervous and Mental Disease</i> , 2021, 209, 820-828.	1.0	3
59	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021, 49, 122-132.	1.0	28
60	Moderators of a resiliency group intervention for frontline clinicians during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021, 293, 373-378.	4.5	8
61	Association of smartphone overuse with depression, anxiety, and other addictive behaviors: A nationwide community sample of Korean adults. <i>Psychiatry Research</i> , 2021, 304, 114133.	3.1	21
62	Increased metabolic variability is associated with newly diagnosed depression: A nationwide cohort study. <i>Journal of Affective Disorders</i> , 2021, 294, 786-793.	4.5	10
63	A Patient With Electroconvulsive Therapy-resistant Major Depressive Disorder With a Full Response to Heated Yoga: A Case Report. <i>Journal of Psychiatric Practice</i> , 2021, 27, 486-491.	0.6	3
64	Associations Between Smoking, Alcohol Consumption, Physical Activity and Depression in Middle-Aged Premenopausal and Postmenopausal Women. <i>Frontiers in Psychiatry</i> , 2021, 12, .	2.4	19
65	High Bodyweight Variability Increases Depression Risk in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea. <i>Frontiers in Psychiatry</i> , 2021, 12, .	2.4	8
66	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. <i>American Journal of Psychiatry</i> , 2020, 177, 143-154.	8.8	111
67	Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea. <i>Sleep</i> , 2020, 43, .	0.9	16
68	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	4.5	29
69	Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 262, 118-125.	4.5	14
70	Elevated Amygdala Activity in Young Adults With Familial Risk for Depression: A Potential Marker of Low Resilience. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 194-202.	1.2	14
71	Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea. <i>Journal of Affective Disorders</i> , 2020, 265, 52-58.	4.5	23
72	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2020, 77, 397.	12.4	83

#	ARTICLE	IF	CITATIONS
73	The Impact of Childhood Trauma, Hallucinations, and Emotional Reactivity on Delusional Ideation. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.4	6
74	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. <i>International Clinical Psychopharmacology</i> , 2020, 35, 313-321.	1.2	13
75	PET imaging of neurotransmission using direct parametric reconstruction. <i>NeuroImage</i> , 2020, 221, 117154.	4.4	5
76	Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2020, 177, 965-973.	8.8	27
77	Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. <i>Journal of Affective Disorders</i> , 2020, 276, 660-666.	4.5	33
78	John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. <i>Pain</i> , 2020, 161, S3-S13.	4.3	27
79	Dose-Dependent Effects of EPA Supplementation on Plasma Specialized Pro-Resolving Mediators in Major Depressive Disorder Patients with Chronic Inflammation. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa068_023.	0.2	0
80	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. <i>Journal of Affective Disorders</i> , 2020, 277, 478-485.	4.5	5
81	Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia. <i>Frontiers in Psychiatry</i> , 2020, 11, .	2.4	5
82	Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2020, 128, 43-51.	2.9	29
83	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. <i>Biological Psychiatry</i> , 2020, 88, 657-667.	5.4	35
84	Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review. <i>Molecular Psychiatry</i> , 2020, 25, 1967-1974.	7.8	16
85	An electroencephalographic signature predicts antidepressant response in major depression. <i>Nature Biotechnology</i> , 2020, 38, 439-447.	29.8	263
86	All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. <i>American Journal of Psychiatry</i> , 2020, 177, 173-174.	8.8	10
87	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. <i>Depression and Anxiety</i> , 2020, 37, 485-495.	4.0	11
88	Evaluating the combination of a Brief Motivational Intervention plus Cognitive Behavioral Therapy for Depression and heavy episodic drinking in college students.. <i>Psychology of Addictive Behaviors</i> , 2020, 34, 308-319.	1.7	17
89	Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial of a Kappa-Selective Opioid Receptor Antagonist Augmentation in Treatment-Resistant Depression. , 2020, 33, 18-26.		9
90	Increased Morbidity of Major Depressive Disorder After Thyroidectomy: A Nationwide Population-Based Study in South Korea. <i>Thyroid</i> , 2019, 29, 1713-1722.	4.4	28

#	ARTICLE	IF	CITATIONS
91	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 2268-2276.	5.3	21
92	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 616-630.	2.7	528
93	Community-Delivered Heated Hatha Yoga as a Treatment for Depressive Symptoms: An Uncontrolled Pilot Study. <i>Journal of Alternative and Complementary Medicine</i> , 2019, 25, 814-823.	1.9	17
94	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019, 110, 166-171.	2.9	60
95	Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. <i>Comprehensive Psychiatry</i> , 2019, 95, 152140.	4.0	16
96	Model-Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1253-1260.	4.7	5
97	Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. <i>Journal of Affective Disorders</i> , 2019, 259, 349-354.	4.5	10
98	Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2019, 258, 102-108.	4.5	18
99	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. <i>Nature Human Behaviour</i> , 2019, 3, 1319-1331.	9.1	48
100	Multiple types of somatic pain increase suicide attempts and depression: A nationwide community sample of Korean adults. <i>Comprehensive Psychiatry</i> , 2019, 90, 43-48.	4.0	16
101	Comparison of suicide attempts in individuals with major depressive disorder with and without history of subthreshold hypomania: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2019, 248, 18-25.	4.5	7
102	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EclinicalMedicine</i> , 2019, 10, 32-41.	8.2	29
103	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. <i>Journal of Affective Disorders</i> , 2019, 256, 8-16.	4.5	16
104	Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder. <i>Scientific Reports</i> , 2019, 9, .	3.4	26
105	Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2019, 33, 511-521.	4.8	29
106	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 691.	12.4	25
107	Childhood trauma history is linked to abnormal brain connectivity in major depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8582-8590.	7.5	208
108	3.4 CHANGES IN AMYGDALA AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SUBCLINICAL PSYCHOSIS: RELATIONSHIP TO SYMPTOM PERSISTENCE, PARANOIA AND ABERRANT SALIENCE. <i>Schizophrenia Bulletin</i> , 2019, 45, S90-S91.	3.9	0

#	ARTICLE	IF	CITATIONS
109	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 428-433.	1.7	23
110	Paranoid Ideation Without Psychosis Is Associated With Depression, Anxiety, and Suicide Attempts in General Population. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 826-831.	1.0	12
111	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. <i>Clinical EEG and Neuroscience</i> , 2019, 50, 3-12.	1.9	31
112	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019, 36, 235-243.	4.0	43
113	Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. <i>Journal of Affective Disorders</i> , 2019, 246, 157-165.	4.5	36
114	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2019, 85, 872-880.	5.4	69
115	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. <i>Journal of Affective Disorders</i> , 2019, 245, 1070-1078.	4.5	32
116	Understanding the effects of emotional reactivity on depression and suicidal thoughts and behaviors: Moderating effects of childhood adversity and resilience. <i>Journal of Affective Disorders</i> , 2019, 245, 419-427.	4.5	102
117	Tachyphylaxis in major depressive disorder: A review of the current state of research. <i>Journal of Affective Disorders</i> , 2019, 245, 488-497.	4.5	39
118	Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. <i>Journal of Affective Disorders</i> , 2019, 243, 516-524.	4.5	158
119	Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial. <i>Journal of Ginseng Research</i> , 2019, 43, 402-407.	5.0	31
120	Discovery and replication of cerebral blood flow differences in major depressive disorder. <i>Molecular Psychiatry</i> , 2019, 25, 1500-1510.	7.8	57
121	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. <i>Molecular Psychiatry</i> , 2019, 25, 1526-1536.	7.8	45
122	Risks of Completed Suicide of Community Individuals with ICD-10 Disorders Across Age Groups: A Nationwide Population-Based Nested Case-Control Study in South Korea. <i>Psychiatry Investigation</i> , 2019, 16, 314-324.	1.6	25
123	Design and Methods of the Korean National Investigations of 70,000 Suicide Victims Through Police Records (The KNIGHTS Study). <i>Psychiatry Investigation</i> , 2019, 16, 777-788.	1.6	10
124	Prospective association between major depressive disorder and leukocyte telomere length over two years. <i>Psychoneuroendocrinology</i> , 2018, 90, 157-164.	2.7	38
125	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. <i>JAMA Psychiatry</i> , 2018, 75, 547.	12.4	180
126	Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence. <i>Addictive Behaviors Reports</i> , 2018, 7, 40-46.	1.7	22

#	ARTICLE	IF	CITATIONS
127	Is It Time for Going Beyond the <i>P</i> -Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 740-749.	1.9	0
128	S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life. <i>Neurotherapeutics</i> , 2018, 15, 156-175.	6.1	109
129	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018, 102, 207-215.	2.9	17
130	A randomized controlled dosing study of Iyengar yoga and coherent breathing for the treatment of major depressive disorder: Impact on suicidal ideation and safety findings. <i>Complementary Therapies in Medicine</i> , 2018, 37, 136-142.	3.0	27
131	The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study. <i>Behavioral Sleep Medicine</i> , 2018, 16, 398-411.	1.9	18
132	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	4.2	51
133	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	1.5	25
134	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. <i>Magnetic Resonance Imaging</i> , 2018, 45, 26-33.	1.8	33
135	Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2018, 227, 323-329.	4.5	23
136	Outcomes of an online computerized cognitive behavioral treatment program for treating Chinese patients with depression: A pilot study. <i>Asian Journal of Psychiatry</i> , 2018, 38, 102-107.	2.5	24
137	Harmonization of cortical thickness measurements across scanners and sites. <i>NeuroImage</i> , 2018, 167, 104-120.	4.4	1,396
138	Efficacy of adjunctive low-dose cariprazine in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2018, 33, 312-321.	1.2	54
139	Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. <i>Frontiers in Psychiatry</i> , 2018, 9, .	2.4	19
140	Increased adrenocorticotrophic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder. <i>Psychiatry Research</i> , 2018, 270, 246-252.	3.1	46
141	Anxiety attacks with or without life-threatening situations, major depressive disorder, and suicide attempt: a nationwide community sample of Korean adults. <i>Psychiatry Research</i> , 2018, 270, 257-263.	3.1	5
142	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , 2018, 36, 634-646.	2.1	136
143	Binge eating, trauma, and suicide attempt in community adults with major depressive disorder. <i>PLoS ONE</i> , 2018, 13, e0198192.	2.3	18
144	Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data. <i>Human Brain Mapping</i> , 2018, 39, 4213-4227.	3.5	441

#	ARTICLE	IF	CITATIONS
145	Sex Differences in the Association between Heavy Drinking and Behavioral Distress Tolerance and Emotional Reactivity Among Non-Depressed College Students. <i>Alcohol and Alcoholism</i> , 2018, 53, 674-681.	1.7	15
146	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. <i>Neuropsychopharmacology</i> , 2018, 43, 2221-2230.	5.3	71
147	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>Focus (American Journal of Psychiatry)</i> , 2018, 116, 1118-1128.	1.1	8
148	Placebo Response as a Latent Characteristic: Application to Analysis of Sequential Parallel Comparison Design Studies. <i>Journal of the American Statistical Association</i> , 2018, 113, 1411-1430.	3.4	6
149	Development and evaluation of a multimodal marker of major depressive disorder. <i>Human Brain Mapping</i> , 2018, 39, 4420-4439.	3.5	46
150	CBT Delivered in a Specialized Depression Clinic for College Students with Depressive Symptoms. <i>Journal of Rational - Emotive and Cognitive - Behavior Therapy</i> , 2018, 37, 52-61.	1.2	6
151	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2018, 25, 1592-1603.	7.8	363
152	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. <i>Molecular Psychiatry</i> , 2018, 25, 1580-1591.	7.8	64
153	Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 55-64.	2.4	101
154	Inflammatory cytokines in major depressive disorder: A case-control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 23-31.	2.4	69
155	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings From the EMBARC Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 138-148.	1.2	21
156	Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study. <i>Advances in Therapy</i> , 2017, 34, 524-541.	3.3	35
157	A comparison of structural connectivity in anxious depression versus non-anxious depression. <i>Journal of Psychiatric Research</i> , 2017, 89, 38-47.	2.9	36
158	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Treatment Response) in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 22-30.	1.2	23
159	Cortical thickness is not associated with current depression in a clinical treatment study. <i>Human Brain Mapping</i> , 2017, 38, 4370-4385.	3.5	18
160	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 2567-2574.	5.3	45
161	Internet Game Addiction, Depression, and Escape From Negative Emotions in Adulthood. <i>Journal of Nervous and Mental Disease</i> , 2017, 205, 568-573.	1.0	90
162	Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. <i>Journal of Psychiatric Research</i> , 2017, 87, 61-70.	2.9	157

#	ARTICLE	IF	CITATIONS
163	Guarding the Gate. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 176-181.	1.7	27
164	Development and validation study of the Smartphone Overuse Screening Questionnaire. <i>Psychiatry Research</i> , 2017, 257, 352-357.	3.1	45
165	Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder. <i>Scientific Reports</i> , 2017, 7, .	3.4	97
166	Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. <i>Journal of Affective Disorders</i> , 2017, 208, 6-14.	4.5	47
167	[P4â€“543]: COGNITIVE FUNCTION AS A PROXY OF FINANCIAL DECISION MAKING IN OLDER PRIMARY CARE ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
168	Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 14, 103-115.	4.2	13
169	Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea. <i>PLoS ONE</i> , 2017, 12, e0174619.	2.3	56
170	Comparisons of Subthreshold Versus Full Posttraumatic Stress Disorder Distinguished by Subjective Functional Impairment Among Train Drivers: A Population-Based Nationwide Study in South Korea. <i>Psychiatry Investigation</i> , 2017, 14, 1.	1.6	8
171	Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. <i>Psychiatry Investigation</i> , 2017, 14, 491.	1.6	3
172	Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2016, 13, 609.	1.6	27
173	Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 130-140.	1.7	50
174	Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 100-109.	1.2	7
175	Loss of sexual interest and premenstrual mood change in women with postpartum versus non-postpartum depression: A nationwide community sample of Korean adults. <i>Journal of Affective Disorders</i> , 2016, 191, 222-229.	4.5	6
176	A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 4-12.	3.0	3
177	Examining the efficacy of d-cycloserine to augment therapeutic learning in depression. <i>Contemporary Clinical Trials</i> , 2016, 48, 146-152.	1.6	12
178	Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice. <i>Neuroscience Letters</i> , 2016, 620, 70-73.	1.9	23
179	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 816-826.	8.8	470
180	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. <i>Journal of Psychiatric Research</i> , 2016, 78, 11-23.	2.9	277

#	ARTICLE	IF	CITATIONS
181	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>American Journal of Psychiatry</i> , 2016, 173, 575-587.	8.8	365
182	Cross-national differences in hypochondriasis symptoms between Korean and American outpatients with major depressive disorder. <i>Psychiatry Research</i> , 2016, 245, 127-132.	3.1	5
183	Major depressive disorder. <i>Nature Reviews Disease Primers</i> , 2016, 2, .	47.2	1,828
184	Linking major depression and the neural substrates of associative processing. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2016, 16, 1017-1026.	1.9	29
185	Ziprasidone augmentation for anxious depression. <i>International Clinical Psychopharmacology</i> , 2016, 31, 341-346.	1.2	9
186	PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, 30-31.	2.7	1
187	Lifetime suicidal ideation and attempt in adults with full major depressive disorder versus sustained depressed mood. <i>Journal of Affective Disorders</i> , 2016, 203, 275-280.	4.5	11
188	Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1296-1306.	1.9	15
189	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2016, 33, 56-65.	4.0	49
190	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 499-508.	8.8	169
191	Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students. <i>Journal of Adolescent Health</i> , 2016, 58, 481-484.	2.7	29
192	Relationship between placebo response rate and clinical trial outcome in bipolar depression. <i>Journal of Psychiatric Research</i> , 2016, 74, 38-44.	2.9	23
193	Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. <i>Neuropsychopharmacology</i> , 2016, 42, 876-885.	5.3	57
194	Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2016, 13, 321.	1.6	27
195	Major depressive disorder with psychosis-like symptoms in Latinos: treatment with and without antipsychotic augmentation. <i>International Journal of Culture and Mental Health</i> , 2015, 8, 137-149.	0.7	1
196	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS'S™ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. <i>Depression and Anxiety</i> , 2015, 32, 605-613.	4.0	39
197	The Role of Anger/Hostility in Treatment-Resistant Depression. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 762-768.	1.0	21
198	Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. <i>Human Brain Mapping</i> , 2015, 36, 3472-3485.	3.5	156

#	ARTICLE	IF	CITATIONS
199	Placebo non-response measure in sequential parallel comparison design studies. <i>Statistics in Medicine</i> , 2015, 34, 2281-2293.	1.7	17
200	Celebrity Suicides and Their Differential Influence on Suicides in the General Population: A National Population-Based Study in Korea. <i>Psychiatry Investigation</i> , 2015, 12, 204.	1.6	16
201	Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. <i>Journal of Psychiatric Research</i> , 2015, 68, 392-396.	2.9	26
202	A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response. <i>Neuropsychopharmacology</i> , 2015, 40, 2588-2595.	5.3	9
203	Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders. <i>Neuron</i> , 2015, 86, 1189-1202.	11.0	119
204	Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression. <i>Biological Psychiatry</i> , 2015, 77, 285-294.	5.4	293
205	Illness beliefs of Chinese American immigrants with major depressive disorder in a primary care setting. <i>Asian Journal of Psychiatry</i> , 2015, 13, 16-22.	2.5	42
206	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. <i>American Journal of Psychiatry</i> , 2015, 172, 881-891.	8.8	94
207	Anhedonia in melancholic and non-melancholic depressive disorders. <i>Journal of Affective Disorders</i> , 2015, 184, 81-88.	4.5	68
208	Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study. <i>Journal of Affective Disorders</i> , 2015, 185, 24-30.	4.5	13
209	Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2015, 172, 1251-1258.	8.8	53
210	Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. <i>Journal of Psychiatric Research</i> , 2015, 62, 56-61.	2.9	6
211	Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. <i>Psychoneuroendocrinology</i> , 2015, 58, 9-22.	2.7	52
212	Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group. <i>Asian Journal of Psychiatry</i> , 2015, 13, 23-29.	2.5	18
213	Screening for Suicide Risk in the College Population. <i>Journal of Rational - Emotive and Cognitive - Behavior Therapy</i> , 2015, 33, 78-94.	1.2	19
214	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 51-56.	1.7	16
215	Predictors of placebo response in bipolar depression. <i>International Clinical Psychopharmacology</i> , 2015, 30, 59-66.	1.2	20
216	Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 1940-1946.	5.3	28

#	ARTICLE	IF	CITATIONS
217	The pro-inflammatory profile of depressed patients is (partly) related to obesity. <i>Journal of Psychiatric Research</i> , 2015, 70, 91-97.	2.9	53
218	Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 187, 183-187.	4.5	29
219	Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. <i>Journal of Psychiatric Research</i> , 2015, 70, 98-105.	2.9	20
220	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. <i>Neuropsychopharmacology</i> , 2015, 41, 454-463.	5.3	99
221	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. <i>PLoS ONE</i> , 2015, 10, e0126326.	2.3	22
222	Paraquat Prohibition and Change in the Suicide Rate and Methods in South Korea. <i>PLoS ONE</i> , 2015, 10, e0128980.	2.3	60
223	A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. <i>primary care companion for CNS disorders</i> , The, 2015, , .	0.6	25
224	Review of Suicide Prevention Programs: Massachusetts, United States, in Comparison with Seoul. <i>Psychiatry Investigation</i> , 2015, 12, 281.	1.6	10
225	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-L-Methionine (SAME) Versus Escitalopram in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 370-376.	1.8	138
226	Effectiveness of the Relaxation Response-Based Group Intervention for Treating Depressed Chinese American Immigrants: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 9186-9201.	2.9	12
227	CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2014, 31, 250-257.	4.0	145
228	Childhood Trauma, Parental Death, and Their Co-occurrence in Relation to Current Suicidality Risk in Adults. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 870-876.	1.0	14
229	Improvement in Subjective and Objective Neurocognitive Functions in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 218-225.	1.7	18
230	Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 332-338.	1.2	6
231	An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. <i>JAMA Psychiatry</i> , 2014, 71, 889.	12.4	138
232	Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 112-117.	4.5	26
233	S-adenosyl methionine (SAME) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response. <i>Journal of Affective Disorders</i> , 2014, 164, 76-81.	4.5	63
234	Associations Among Smoking, Anhedonia, and Reward Learning in Depression. <i>Behavior Therapy</i> , 2014, 45, 651-663.	2.9	74

#	ARTICLE	IF	CITATIONS
235	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). <i>Journal of Affective Disorders</i> , 2014, 163, 18-24.	4.5	38
236	Fatigue across the CNS spectrum: a clinical review. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2014, 2, 231-246.	1.5	2
237	Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients. <i>European Neuropsychopharmacology</i> , 2014, 24, 1188-1195.	1.0	10
238	Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. <i>Journal of Affective Disorders</i> , 2014, 168, 439-451.	4.5	59
239	Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 113-118.	3.8	81
240	The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 1-10.	4.0	58
241	Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder. <i>Biological Psychiatry</i> , 2014, 76, 536-541.	5.4	69
242	Feelings of worthlessness, traumatic experience, and their comorbidity in relation to lifetime suicide attempt in community adults with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 206-212.	4.5	41
243	Sleep Quality, Posttraumatic Stress, Depression, and Human Errors in Train Drivers: A Population-Based Nationwide Study in South Korea. <i>Sleep</i> , 2014, 37, 1969-1975.	0.9	16
244	Evaluation of Opioid Modulation in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 40, 1448-1455.	5.3	160
245	Using online social media, Facebook, in screening for major depressive disorder among college students. <i>International Journal of Clinical and Health Psychology</i> , 2013, 13, 74-80.	4.1	43
246	Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder. <i>Psychiatry Research</i> , 2013, 210, 951-956.	3.1	27
247	RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, ANXIETY, AND FUNCTIONING IN COLLEGE STUDENTS. <i>Depression and Anxiety</i> , 2013, 30, 873-880.	4.0	206
248	A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. <i>Statistics in Medicine</i> , 2013, 32, 2767-2789.	1.7	48
249	Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos. <i>Journal of Affective Disorders</i> , 2013, 150, 578-584.	4.5	16
250	Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2013, 148, 368-374.	4.5	27
251	Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. <i>Journal of Women's Health</i> , 2013, 22, 121-131.	2.1	66
252	Combined MI + CBT for Depressive Symptoms and Binge Drinking Among Young Adults: Two Case Studies. <i>Journal of Cognitive Psychotherapy</i> , 2013, 27, 235-257.	0.9	4

#	ARTICLE	IF	CITATIONS
253	Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. <i>Journal of Psychopharmacology</i> , 2013, 27, 424-434.	4.8	66
254	Relationship Between Obesity and Depression. <i>Psychosomatic Medicine</i> , 2013, 75, 863-872.	2.2	53
255	Massachusetts General Hospital SAFER Criteria for Clinical Trials and Research. <i>Harvard Review of Psychiatry</i> , 2013, 21, 269-274.	1.9	28
256	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. <i>American Journal of Psychiatry</i> , 2013, 170, 207-217.	8.8	241
257	Correlates of Irritability in College Students With Depressive Symptoms. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 953-958.	1.0	22
258	The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. <i>International Clinical Psychopharmacology</i> , 2013, 28, 238-244.	1.2	8
259	Childhood Parental Death and Lifetime Suicide Attempt of the Opposite-Gender Offspring in a Nationwide Community Sample of Korea. <i>Suicide and Life-Threatening Behavior</i> , 2013, 43, 598-610.	2.3	20
260	Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 827-830.	1.7	5
261	A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e636-e641.	1.8	83
262	S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders. <i>CNS Drugs</i> , 2012, 6, 416-425.	6.3	17
263	Severe Depression. <i>CNS Drugs</i> , 2012, 15, 765-776.	6.3	42
264	GABAB Receptors, Schizophrenia and Sleep Dysfunction. <i>CNS Drugs</i> , 2012, PAP, .	6.3	230
265	A Randomized, Controlled, Pilot Study of Acamprosate Added to Escitalopram in Adults With Major Depressive Disorder and Alcohol Use Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 787-796.	1.7	21
266	Major Depressive Disorder With Psychosis-Like Symptoms Among Latinos. <i>Psychiatric Services</i> , 2012, 63, 482-487.	2.0	13
267	The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1165-1172.	2.4	24
268	The Inflammatory Hypothesis of Depression. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 413-421.	1.1	4
269	Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study. <i>American Journal of Psychiatry</i> , 2012, 169, 1065-1072.	8.8	74
270	5-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials. <i>American Journal of Psychiatry</i> , 2012, 169, 1267-1274.	8.8	256

#	ARTICLE	IF	CITATIONS
271	Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. <i>BMJ Open</i> , 2012, 2, e000544.	1.9	49
272	The Quick Inventory of Depressive Symptomatology, Clinician Rated and Self-report. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 712-715.	1.0	28
273	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1387-1399.	2.7	27
274	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial. <i>European Neuropsychopharmacology</i> , 2012, 22, 183-199.	1.0	72
275	An exploratory study of combination bupropion and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. <i>Journal of Psychiatric Research</i> , 2012, 46, 1553-1563.	2.9	60
276	Cross-Cultural Aspects of Depression Management in Primary Care. <i>Current Psychiatry Reports</i> , 2012, 14, 336-344.	5.3	10
277	Cognitive therapy for anxious depression in STARbD: What have we learned?. <i>Journal of Affective Disorders</i> , 2012, 142, 213-218.	4.5	48
278	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. <i>Depression and Anxiety</i> , 2012, 29, 94-101.	4.0	33
279	EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL. <i>Depression and Anxiety</i> , 2012, 29, 111-122.	4.0	19
280	CLINICAL OUTCOMES IN MEASUREMENT-BASED TREATMENT (COMET): A TRIAL OF DEPRESSION MONITORING AND FEEDBACK TO PRIMARY CARE PHYSICIANS. <i>Depression and Anxiety</i> , 2012, 29, 865-873.	4.0	63
281	Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in Measurement-based Treatment (COMET) trial. <i>General Hospital Psychiatry</i> , 2012, 34, 105-112.	2.6	30
282	Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 441-451.	5.0	41
283	Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2012, 46, 64-71.	2.9	83
284	Development of a clinical global impression scale for fatigue. <i>Journal of Psychiatric Research</i> , 2012, 46, 370-374.	2.9	32
285	A mega-analysis of genome-wide association studies for major depressive disorder. <i>Molecular Psychiatry</i> , 2012, 18, 497-511.	7.8	1,048
286	Do Suicidal Thoughts or Behaviors Recur During a Second Antidepressant Treatment Trial?. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1439-1442.	1.8	9
287	Eszopiclone Treatment for Insomnia. primary care companion for CNS disorders, <i>The</i> , 2012, , .	0.6	14
288	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2011, 68, 351.	12.6	124

#	ARTICLE	IF	CITATIONS
289	Using the Electronic Medical Record to Examine Racial and Ethnic Differences in Depression Diagnosis and Treatment in a Primary Care Population. <i>Primary Health Care: Open Access</i> , 2011, 01, .	0.1	0
290	The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 31-38.	1.7	16
291	A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 597-602.	1.7	11
292	Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (<i>Hypericum</i>) Tj ETQq0 0 0 rBT /Overbook 10 Tf 5		
293	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. <i>Journal of Psychiatric Research</i> , 2011, 45, 64-75.	2.9	45
294	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. <i>Journal of Affective Disorders</i> , 2011, 133, 467-476.	4.5	46
295	Assessing anxious features in depressed outpatients. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, .	2.2	18
296	The Engagement Interview Protocol (EIP): improving the acceptance of mental health treatment among Chinese immigrants. <i>International Journal of Culture and Mental Health</i> , 2011, 4, 91-105.	0.7	17
297	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. <i>American Journal of Psychiatry</i> , 2011, 168, 689-701.	8.8	368
298	Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial. <i>Psychiatric Services</i> , 2011, 62, 1167-1179.	2.0	33
299	A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 473-479.	1.8	36
300	Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 914-928.	1.8	82
301	Association Between Patient Beliefs Regarding Assigned Treatment and Clinical Response. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1669-1676.	1.8	52
302	Concise Health Risk Tracking Scale. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 757-764.	1.8	149
303	Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 303-309.	1.5	50
304	Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans in Primary Care. <i>American Journal of Public Health</i> , 2010, 100, 2397-2402.	2.7	112
305	Do atypical features affect outcome in depressed outpatients treated with citalopram?. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 15.	2.7	60
306	S -Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2010, 167, 942-948.	8.8	293

#	ARTICLE	IF	CITATIONS
307	Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 17-21.	1.2	20
308	Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 259-266.	1.7	23
309	The impact of diabetes on depression treatment outcomes. <i>General Hospital Psychiatry</i> , 2010, 32, 33-41.	2.6	28
310	Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. <i>Annals of General Psychiatry</i> , 2010, 9, .	2.3	13
311	Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study. <i>Neuropsychopharmacology</i> , 2010, 35, 2339-2345.	5.3	125
312	Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response. <i>Archives of General Psychiatry</i> , 2010, 67, 369.	12.6	107
313	Genome-Wide Association Study of Suicide Attempts in Mood Disorder Patients. <i>American Journal of Psychiatry</i> , 2010, 167, 1499-1507.	8.8	148
314	Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence. <i>Biological Psychiatry</i> , 2010, 67, 722-729.	5.4	391
315	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2010, 107, 161-170.	2.9	78
316	RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 322-325.	5.0	150
317	Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis. <i>European Neuropsychopharmacology</i> , 2010, 20, 562-567.	1.0	15
318	Microstructural Abnormalities in Subcortical Reward Circuitry of Subjects with Major Depressive Disorder. <i>PLoS ONE</i> , 2010, 5, e13945.	2.3	120
319	Complementary and Alternative Medicine in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 669-681.	1.8	123
320	Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009, 11, 344-352.	0.7	25
321	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 956-967.	2.4	9
322	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. <i>International Journal of Cognitive Therapy</i> , 2009, 2, 66-87.	1.2	2
323	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. <i>American Journal of Psychiatry</i> , 2009, 166, 599-607.	8.8	219
324	Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. <i>Neuropsychopharmacology</i> , 2009, 34, 1819-1828.	5.3	94

#	ARTICLE	IF	CITATIONS
325	Reduced Caudate and Nucleus Accumbens Response to Rewards in Unmedicated Individuals With Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2009, 166, 702-710.	8.8	1,125
326	Sex differences in response to citalopram: A STAR [®] -D report. <i>Journal of Psychiatric Research</i> , 2009, 43, 503-511.	2.9	179
327	Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2009, 113, 263-271.	4.5	23
328	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR [®] -D study. <i>Journal of Affective Disorders</i> , 2009, 117, 63-73.	4.5	95
329	Diurnal mood variation in outpatients with major depressive disorder. <i>Depression and Anxiety</i> , 2009, 26, 851-863.	4.0	28
330	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR [®] -D trial. <i>Depression and Anxiety</i> , 2009, 26, 612-621.	4.0	29
331	Release bias in accessing medical records in clinical trials: a STAR [®] -D report. <i>International Journal of Methods in Psychiatric Research</i> , 2009, 18, 147-158.	2.2	1
332	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. <i>Drug and Alcohol Dependence</i> , 2009, 99, 248-260.	2.9	135
333	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. <i>Psychiatry Research</i> , 2009, 169, 132-138.	3.1	112
334	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study. <i>Psychiatry Research</i> , 2009, 169, 124-131.	3.1	169
335	Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. <i>European Neuropsychopharmacology</i> , 2009, 19, 34-40.	1.0	357
336	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2009, 19, 772-777.	1.0	169
337	The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR [®] -D Report. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 320-332.	5.0	11
338	Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. <i>International Clinical Psychopharmacology</i> , 2009, 24, 19-25.	1.2	39
339	Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 222-230.	1.7	72
340	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 260, 145-150.	2.7	37
341	Do Depressed Patients With Diabetes Experience More Side Effects When Treated With Citalopram Than Their Counterparts Without Diabetes?. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009, 11, 186-196.	0.7	2
342	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR [®] -D. <i>Journal of General Internal Medicine</i> , 2008, 23, 551-560.	2.4	96

#	ARTICLE	IF	CITATIONS
343	Redefining Affective Disorders: Relevance for Drug Development. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 2-9.	5.0	16
344	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: A STAR*D report. <i>Journal of Affective Disorders</i> , 2008, 108, 113-120.	4.5	16
345	Reduced hedonic capacity in major depressive disorder: Evidence from a probabilistic reward task. <i>Journal of Psychiatric Research</i> , 2008, 43, 76-87.	2.9	714
346	Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. <i>Biological Psychiatry</i> , 2008, 63, 699-704.	5.4	255
347	Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2008, 63, 1127-1134.	5.4	165
348	Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression. <i>Psychiatry Research</i> , 2008, 161, 302-308.	3.1	31
349	Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. <i>Psychiatry Research</i> , 2008, 161, 116-120.	3.1	45
350	A Double-Blind, Randomized, Pilot Dose-Finding Study of Maca Root (<i>L. Meyenii</i>) for the Management of SSRI-Induced Sexual Dysfunction. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 182-191.	5.0	80
351	Treatment Outcomes for Older Depressed Patients With Earlier Versus Late Onset of First Depressive Episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 58-64.	1.7	41
352	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2008, 37, 714-724.	3.7	65
353	Adaptation of Dialectical Behavior Therapy Skills Training Group for Treatment-Resistant Depression. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 136-143.	1.0	155
354	Selecting Among Second-Step Antidepressant Medication Monotherapies. <i>Archives of General Psychiatry</i> , 2008, 65, 870.	12.6	164
355	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2008, 165, 342-351.	8.8	872
356	Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. <i>Neuropsychopharmacology</i> , 2008, 33, 2810-2819.	5.3	97
357	Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression. <i>Annals of Clinical Psychiatry</i> , 2008, 20, 209-218.	1.4	56
358	Association of a Polymorphism Near CREB1 With Differential Aversion Processing in the Insula of Healthy Participants. <i>Archives of General Psychiatry</i> , 2008, 65, 882.	12.6	49
359	The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 156-165.	1.7	499
360	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 128-142.	1.1	22

#	ARTICLE	IF	CITATIONS
361	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1136-1147.	8.8	178
362	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 104-119.	1.1	2
363	A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 660-666.	1.7	60
364	A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 428-436.	1.3	62
365	An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. <i>Journal of Psychiatric Practice</i> , 2008, 14, 271-280.	0.6	46
366	A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2008, 23, 269-275.	1.2	31
367	Clinically Relevant Findings from STAR*D. <i>Psychiatric Annals</i> , 2008, 38, .	0.3	13
368	The STAR*D study: treating depression in the real world.. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 57-66.	1.3	211
369	The History and Current State of Antidepressant Clinical Trial Design. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1513-1528.	1.8	71
370	Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 440-447.	0.7	43
371	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2007, 164, 739-752.	8.8	312
372	Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study. <i>Archives of General Psychiatry</i> , 2007, 64, 689.	12.6	135
373	Modafinil Augmentation of Selective Serotonin Reuptake Inhibitor Therapy in MDD Partial Responders with Persistent Fatigue and Sleepiness. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 153-159.	1.4	102
374	The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 187-195.	1.4	25
375	Insured and Non-insured Depressed Outpatients: How Do They Compare?. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 73-82.	1.4	5
376	Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2007, 164, 753-760.	8.8	69
377	Effect of Age at Onset on the Course of Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2007, 164, 1539-1546.	8.8	480
378	Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 783.	12.6	214

#	ARTICLE	IF	CITATIONS
379	Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis. <i>Annals of Family Medicine</i> , 2007, 5, 126-134.	1.8	94
380	Extreme response style in recurrent and chronically depressed patients: Change with antidepressant administration and stability during continuation treatment. <i>Journal of Consulting and Clinical Psychology</i> , 2007, 75, 145-153.	2.3	28
381	Comparison of Quality of Life Measures in a Depressed Population. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 219-225.	1.0	28
382	Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors. <i>International Journal of Psychiatry in Medicine</i> , 2007, 37, 99-111.	1.3	16
383	Perceived Stress and Cognitive Vulnerability Mediate the Effects of Personality Disorder Comorbidity on Treatment Outcome in Major Depressive Disorder. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 729-737.	1.0	19
384	Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. <i>Psychiatry Research</i> , 2007, 149, 195-200.	3.1	28
385	Pain in depression: STAR*D study findings. <i>Journal of Psychosomatic Research</i> , 2007, 63, 113-122.	2.1	73
386	A meta-analysis of clinical trials comparing milnacipran, a serotonin/norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2007, 17, 32-36.	1.0	48
387	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. <i>Psychosomatics</i> , 2007, 48, 418-425.	2.6	31
388	A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression. <i>Psychiatric Clinics of North America</i> , 2007, 30, 13-29.	2.1	39
389	Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. <i>Biological Psychiatry</i> , 2007, 62, 1217-1227.	5.4	285
390	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. <i>Psychoneuroendocrinology</i> , 2007, 32, 843-853.	2.7	80
391	Family history of mood disorder and characteristics of major depressive disorder: A STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Psychiatric Research</i> , 2007, 41, 214-221.	2.9	73
392	The STAR*D project results: A comprehensive review of findings. <i>Current Psychiatry Reports</i> , 2007, 9, 449-459.	5.3	661
393	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. <i>Journal of Youth and Adolescence</i> , 2007, 37, 906-916.	2.6	91
394	The Role of Cognitive-Behavioral Therapy and Fluoxetine in Prevention of Recurrence of Major Depressive Disorder. <i>Cognitive Therapy and Research</i> , 2007, 34, 13-23.	1.5	14
395	Clinical Features of Depression in Outpatients With and Without Co-Occurring General Medical Conditions in STAR*D. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2007, 09, 7-15.	0.7	60
396	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. <i>New England Journal of Medicine</i> , 2006, 354, 1231-1242.	34.6	995

#	ARTICLE	IF	CITATIONS
397	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. <i>American Journal of Human Genetics</i> , 2006, 78, 804-814.	6.5	453
398	Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine. <i>Psychosomatics</i> , 2006, 47, 348-352.	2.6	22
399	An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. <i>Biological Psychiatry</i> , 2006, 59, 493-501.	5.4	367
400	Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine. <i>Biological Psychiatry</i> , 2006, 60, 270-274.	5.4	30
401	Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. <i>Biological Psychiatry</i> , 2006, 59, 1052-1060.	5.4	457
402	Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging. <i>Biological Psychiatry</i> , 2006, 60, 432-435.	5.4	470
403	Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors. <i>Biological Psychiatry</i> , 2006, 60, 1350-1355.	5.4	331
404	A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 783-790.	2.7	45
405	Tranlycypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1531-1541.	8.8	319
406	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 823-835.	2.7	167
407	A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 216-218.	1.7	0
408	Clinical characteristics of depressed patients with comorbid diabetes mellitus. <i>International Clinical Psychopharmacology</i> , 2006, 21, 43-47.	1.2	6
409	Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. <i>American Journal on Addictions</i> , 2006, 15, 278-285.	1.9	95
410	Adjunctive atomoxetine for residual fatigue in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2006, 40, 370-373.	2.9	25
411	Management of depression relapse: Re-initiation of duloxetine treatment or dose increase. <i>Journal of Psychiatric Research</i> , 2006, 40, 328-336.	2.9	32
412	Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. <i>Human Psychopharmacology</i> , 2006, 21, 221-225.	1.7	3
413	Remissions in Maternal Depression and Child Psychopathology. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1389.	16.6	567
414	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-1172.	8.8	301

#	ARTICLE	IF	CITATIONS
415	Clinical and Demographic Factors Associated With DSM-IV Melancholic Depression. <i>Annals of Clinical Psychiatry</i> , 2006, 18, 91-98.	1.4	113
416	Pharmacological approaches to the treatment of residual symptoms. <i>Journal of Psychopharmacology</i> , 2006, 20, 29-34.	4.8	40
417	A Comparison of Lithium and T ₃ Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1519-1530.	8.8	555
418	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. <i>American Journal of Psychiatry</i> , 2006, 163, 28-40.	8.8	3,611
419	Medication Augmentation after the Failure of SSRIs for Depression. <i>New England Journal of Medicine</i> , 2006, 354, 1243-1252.	34.6	951
420	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1905-1917.	8.8	5,061
421	Efficacy and Safety of Sildenafil in Men With Serotonergic Antidepressant-Associated Erectile Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 240-246.	1.8	75
422	Use of Treatment Algorithms for Depression. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1458-1465.	1.8	15
423	A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1754-1759.	1.8	201
424	Commentary. primary care companion for CNS disorders, <i>The</i> , 2006, 8, .	0.6	12
425	The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 523.	2.7	84
426	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	1.7	119
427	Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 336-341.	1.7	101
428	An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 552-560.	1.7	24
429	Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder. <i>Psychosomatic Medicine</i> , 2005, 67, 703-706.	2.2	57
430	Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. <i>Journal of Affective Disorders</i> , 2005, 87, 43-55.	4.5	218
431	Immediate Switching of Antidepressant Therapy: Results from a Clinical Trial of Duloxetine. <i>Annals of Clinical Psychiatry</i> , 2005, 17, 259-268.	1.4	19
432	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American)</i> Tj ETQq0 0,0 rgBT /Oyerlock 10	1.1	2

#	ARTICLE	IF	CITATIONS
433	Relationships between major depressive disorder and comorbid anxiety and personality disorders. <i>Comprehensive Psychiatry</i> , 2005, 46, 266-271.	4.0	32
434	Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses. <i>Current Therapeutic Research</i> , 2005, 66, 522-540.	1.3	29
435	PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Depression and Renal Disease. <i>Seminars in Dialysis</i> , 2005, 18, 73-81.	1.1	41
436	A Multicenter, Placebo-Controlled Study of Modafinil Augmentation in Partial Responders to Selective Serotonin Reuptake Inhibitors With Persistent Fatigue and Sleepiness. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 85-93.	1.8	172
437	15 Years of Clinical Experience With Bupropion HCl. primary care companion for CNS disorders, <i>The</i> , 2005, 7, .	0.6	232
438	Ventromedial Prefrontal Cortex and Amygdala Dysfunction During an Anger Induction Positron Emission Tomography Study in Patients With Major Depressive Disorder With Anger Attacks. <i>Archives of General Psychiatry</i> , 2004, 61, 795.	12.6	151
439	Tolerability Issues During Long-Term Treatment with Antidepressants. <i>Annals of Clinical Psychiatry</i> , 2004, 16, 15-25.	1.4	139
440	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). <i>Journal of Psychiatric Research</i> , 2004, 38, 241-248.	2.9	7
441	Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. <i>Journal of Psychiatric Research</i> , 2004, 38, 583-589.	2.9	25
442	The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. <i>Journal of Affective Disorders</i> , 2004, 79, 291-295.	4.5	82
443	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004, 25, 119-142.	2.8	987
444	Quality of life assessments in major depressive disorder: a review of the literature. <i>General Hospital Psychiatry</i> , 2004, 26, 13-17.	2.6	280
445	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. <i>General Hospital Psychiatry</i> , 2004, 26, 421-429.	2.6	118
446	Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. <i>Current Psychiatry Reports</i> , 2004, 6, 193-201.	5.3	62
447	Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. <i>European Neuropsychopharmacology</i> , 2004, 14, 135-142.	1.0	127
448	Factors that differentiate early vs. later onset of major depression disorder. <i>Psychiatry Research</i> , 2004, 129, 127-140.	3.1	135
449	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. <i>Psychosomatics</i> , 2004, 45, 224-229.	2.6	28
450	Comorbid Medical Illness and Relapse of Major Depressive Disorder in the Continuation Phase of Treatment. <i>Psychosomatics</i> , 2004, 45, 419-425.	2.6	51

#	ARTICLE	IF	CITATIONS
451	Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 467-469.	1.7	10
452	The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 521-530.	1.8	184
453	S-adenosyl-methionine in depression: A comprehensive review of the literature. <i>Current Psychiatry Reports</i> , 2003, 5, 460-466.	5.3	91
454	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR [®] -D) study. <i>Psychiatric Clinics of North America</i> , 2003, 26, 457-494.	2.1	476
455	Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). <i>Biological Psychiatry</i> , 2003, 53, 1028-1042.	5.4	513
456	Diagnosis and definition of treatment-resistant depression. <i>Biological Psychiatry</i> , 2003, 53, 649-659.	5.4	1,255
457	Somatic symptoms in treatment-resistant depression. <i>Psychiatry Research</i> , 2003, 118, 39-45.	3.1	50
458	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , 2003, 118, 183-188.	3.1	26
459	Treatment of Antidepressant-Associated Sexual Dysfunction With Sildenafil. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 56.	16.6	190
460	HOPELESSNESS AND SUICIDAL IDEATION IN OUTPATIENTS WITH TREATMENT-RESISTANT DEPRESSION: PREVALENCE AND IMPACT ON TREATMENT OUTCOME. <i>Journal of Nervous and Mental Disease</i> , 2003, 191, 444-449.	1.0	57
461	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2003, 160, 2122-2127.	8.8	117
462	A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. <i>International Clinical Psychopharmacology</i> , 2003, 18, 293-296.	1.2	5
463	Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 365-369.	1.7	29
464	Title is missing!. <i>Annals of Clinical Psychiatry</i> , 2003, 15, 17-22.	1.4	16
465	Fluoxetine treatment of depressed patients with comorbid anxiety disorders. <i>Journal of Psychopharmacology</i> , 2002, 16, 215-219.	4.8	20
466	Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 474-480.	1.7	64
467	Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 379-387.	1.7	120
468	Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 137-147.	1.7	83

#	ARTICLE	IF	CITATIONS
469	Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence,,,, American Journal of Clinical Nutrition, 2002, 76, 1158S-1161S.	4.7	234
470	Depression and public health. Journal of Psychosomatic Research, 2002, 53, 849-857.	2.1	473
471	Elevated Cholesterol Levels Associated With Nonresponse to Fluoxetine Treatment in Major Depressive Disorder. Psychosomatics, 2002, 43, 310-316.	2.6	71
472	A survey of prescribing practices in the treatment of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 177-187.	3.8	65
473	An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Research - Neuroimaging, 2002, 116, 151-161.	1.8	37
474	Title is missing!. Annals of Clinical Psychiatry, 2002, 14, 33-38.	1.4	44
475	Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence,,,, American Journal of Clinical Nutrition, 2002, 76, 1158S-1161S.	4.7	86
476	Somatic Symptoms, Depression, and Antidepressant Treatment. Journal of Clinical Psychiatry, 2002, 63, 305-307.	1.8	80
477	Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. Journal of Affective Disorders, 2000, 59, 119-126.	4.5	111
478	Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Research, 2000, 94, 9-18.	3.1	79
479	Major Depressive Disorder. Neuron, 2000, 28, 335-341.	11.0	549
480	Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. Journal of Affective Disorders, 1999, 52, 217-223.	4.5	31
481	Strategies for Augmentation of SSRI Treatment: A Survey of an Academic Psychopharmacology Practice. Harvard Review of Psychiatry, 1999, 6, 322-326.	1.9	13
482	Anger attacks in depression. Depression and Anxiety, 1998, 8, 59-63.	4.0	51
483	A Cross-Sectional Study of Private Psychiatric Practices under a Single-Payer Health Care System. Canadian Journal of Psychiatry, 1997, 42, 395-401.	2.7	4
484	Are Dependency and Self-Criticism Risk Factors for Major Depressive Disorder?. Canadian Journal of Psychiatry, 1997, 42, 291-297.	2.7	7
485	Major depressive subtypes and treatment response. Biological Psychiatry, 1997, 42, 568-576.	5.4	241
486	DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION. Psychiatric Clinics of North America, 1996, 19, 179-200.	2.1	698

#	ARTICLE	IF	CITATIONS
487	Consumption of Alcohol, Nicotine, and Caffeine Among Depressed Outpatients. <i>Psychosomatics</i> , 1996, 37, 518-522.	2.6	73
488	Hostility changes following antidepressant treatment: Relationship to stress and negative thinking. <i>Journal of Psychiatric Research</i> , 1996, 30, 459-467.	2.9	27
489	Continuation and Maintenance Treatments of Major Depressive Disorder. <i>Psychiatric Annals</i> , 1994, 24, 281-290.	0.3	41
490	An Open Trial of Methyltetrahydrofolate in Elderly Depressed Patients. <i>Annals of Clinical Psychiatry</i> , 1993, 5, 101-105.	1.4	65
491	Prolactin and stress. <i>Stress and Health</i> , 1987, 3, 211-216.	0.6	16
492	Nutrition and Depression: The Role of Folate. <i>Nutrition Reviews</i> , 0, 55, 145-149.	5.6	156
493	Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. <i>International Journal of Neuropsychopharmacology</i> , 0, , pyw087.	2.7	17
494	Similar Changes in Cognitions following Cognitive-Behavioral Therapy or Escitalopram for Major Depressive Disorder: Implications for Mechanisms of Change. <i>Annals of Clinical Psychiatry</i> , 0, 27, 118-126.	1.4	2
495	Nsi-189 Phosphate, A Novel Neurogenic Compound, Selectively Benefits Moderately Depressed Patients: A Post-Hoc Analysis of A Phase 2 Study of Major Depressive Disorder. <i>Annals of Clinical Psychiatry</i> , 0, 32, 182-196.	1.4	0
496	College Students with Depressive Symptoms with and without Fatigue: Differences in Functioning, Suicidality, Anxiety, and Depressive Severity. <i>Annals of Clinical Psychiatry</i> , 0, 27, 100-108.	1.4	0
497	Rising Placebo Response Rates Threaten the Validity of Antipsychotic Meta-Analyses. <i>Annals of Clinical Psychiatry</i> , 0, 31, 249-259.	1.4	1
498	Further Evidence for the Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). <i>Annals of Clinical Psychiatry</i> , 0, 26, 270-280.	1.4	1
499	What is the Overlap between Subjective and Objective Cognitive Impairments in Mdd?. <i>Annals of Clinical Psychiatry</i> , 0, 30, 176-184.	1.4	3
500	Factors that Distinguish College Students with Depressive Symptoms with and without Suicidal Thoughts. <i>Annals of Clinical Psychiatry</i> , 0, 25, 41-49.	1.4	1
501	Estimating Causal Treatment Effects in the Sequential Parallel Comparison Design (SPCD). <i>Statistics in Medicine</i> , 0, 44, .	1.7	0
502	Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial. <i>American Journal of Psychiatry</i> , 0, 182, 1072-1082.	8.8	2